CLIMB BIO, INC. Foreign Currency Transaction Loss, before Tax
CLIMB BIO, INC. (CLYM) reported Foreign Currency Transaction Loss, before Tax of $1.25 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionLossBeforeTax · last filed 2023-03-06
- CLIMB BIO, INC. foreign currency transaction loss, before tax for the quarter ending 2022-12-31 was -$1.26M, a 2172.13% decline year-over-year.
- CLIMB BIO, INC. foreign currency transaction loss, before tax for the quarter ending 2022-09-30 was $1.32M, a 422.62% increase year-over-year.
- CLIMB BIO, INC. foreign currency transaction loss, before tax for the quarter ending 2022-06-30 was $1.04M, a 8583.33% increase year-over-year.
- CLIMB BIO, INC. foreign currency transaction loss, before tax for the quarter ending 2022-03-31 was $157.00K.
- CLIMB BIO, INC. foreign currency transaction loss, before tax for fiscal 2022 was $1.25M, a 280.55% increase from fiscal 2021.
- CLIMB BIO, INC. foreign currency transaction loss, before tax for fiscal 2021 was $329.00K.
| Period end | Foreign Currency Transaction Loss, before Tax 3 month | Foreign Currency Transaction Loss, before Tax 6 month | Foreign Currency Transaction Loss, before Tax 9 month | Foreign Currency Transaction Loss, before Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $53.00K derived: sum of 2 quarters · filed 2023-03-06 | $1.09M derived: sum of 3 quarters · filed 2023-03-06 | $1.25M 10-K · filed 2023-03-06 |
| 2022-09-30 | $1.32M 10-Q · filed 2022-11-14 | $2.36M derived: sum of 2 quarters · filed 2022-11-14 | $2.52M 10-Q · filed 2022-11-14 | $2.58M derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | $1.04M 10-Q · filed 2022-08-15 | $1.20M 10-Q · filed 2022-08-15 | $1.26M derived: sum of 3 quarters · filed 2023-03-06 | $1.51M derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $157.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-06 | $218.00K derived: sum of 2 quarters · filed 2023-03-06 | $470.00K derived: sum of 3 quarters · filed 2023-03-06 | $482.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $313.00K derived: sum of 2 quarters · filed 2023-03-06 | $325.00K derived: sum of 3 quarters · filed 2023-03-06 | $329.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $252.00K 10-Q · filed 2022-11-14 | $264.00K derived: sum of 2 quarters · filed 2022-11-14 | $268.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $12.00K 10-Q · filed 2022-08-15 | $16.00K 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |